Investigation into Atkore and Others by Johnson Fistel
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy CAPR?
Source: Globenewswire
- Shareholder Investigation: Johnson Fistel, PLLP is investigating whether executives at Atkore Inc. and others breached their fiduciary duties, allowing shareholders who held shares continuously since specific dates to seek corporate governance reforms.
- Antitrust Allegations: Atkore is accused in a lawsuit of colluding with other PVC pipe manufacturers to engage in price-fixing, which artificially inflated prices and led to a significant decline in pricing once exposed, severely impacting the company's operations.
- Lack of Transparency at Axsome: Axsome Therapeutics faces allegations of failing to disclose critical chemistry and manufacturing issues during the preparation of its New Drug Application, potentially jeopardizing its market prospects and investor confidence.
- CTO's Financial Misrepresentation: CTO Realty Growth is accused of misleading investors about the sustainability of its dividends and using deceptive practices to inflate its financial performance, undermining investor trust in the company's future prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CAPR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CAPR
Wall Street analysts forecast CAPR stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 33.570
Low
45.00
Averages
51.57
High
60.00
Current: 33.570
Low
45.00
Averages
51.57
High
60.00
About CAPR
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. It leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins, and small molecule therapeutics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Capricor Stock Jumps 11% Following FDA's Resumption of Review for Muscle-Wasting Drug
- Stock Performance: Capricor's shares rose by 11% following a review of the company's drug for muscle-wasting conditions.
- Drug Review Impact: The positive market reaction is attributed to the favorable assessment of Capricor's treatment, which targets specific health issues.
See More
Capricor Therapeutics Inc. Announces PDUFA Target Action Date for DeramioCel on August 22, 2026
- Target Action Date: The target action date for the drug Deramciclus has been set for August 22, 2026.
- Company Involved: The announcement pertains to Capricor Therapeutics, which is involved in the development of this therapeutic.
See More
Deramiocel Poised to Be First Therapy for DMD's Cardiac and Skeletal Issues
- FDA Review Resumed: The FDA has lifted the Complete Response Letter for Capricor Therapeutics' Deramiocel BLA, resuming its review with a target action date of August 22, 2026, which opens significant market opportunities for the company.
- Clinical Trial Success: Deramiocel achieved its primary endpoint and all Type I error-controlled secondary endpoints in the HOPE-3 Phase 3 trial, demonstrating its potential as the first therapy to address both skeletal and cardiac manifestations of Duchenne muscular dystrophy (DMD).
- Priority Review Eligibility: The company expects to qualify for a Priority Review Voucher (PRV) upon potential approval of Deramiocel, which would expedite its market entry and enhance its competitive position in the rare disease treatment landscape.
- Significant Market Potential: DMD affects approximately 15,000 individuals in the U.S., with limited treatment options currently available; the successful launch of Deramiocel would provide new hope for patients while generating substantial economic returns for Capricor.
See More
Capricor's New Therapy Shows Heart Function Improvement
- Clinical Trial Data: Capricor Therapeutics showcased significant improvements in heart function for Duchenne muscular dystrophy patients in its HOPE-3 trial, with cardiac MRI indicating a notable reduction in fibrosis, suggesting substantial treatment efficacy.
- Key Metric Improvement: After 12 months of treatment, patients with baseline cardiomyopathy experienced a 3.3 percentage-point increase in left ventricular ejection fraction, highlighting Deramiocel's potential to enhance heart health and improve patient quality of life.
- FDA Application Progress: Capricor has submitted a Biologics License Application for Deramiocel to the U.S. FDA, which is currently under review, with a decision expected on August 22, 2026, marking a critical milestone for the company's future prospects.
- Market Reaction: Following the release of new data, CAPR stock rose approximately 2% at the opening bell, yet the market remains cautious about the long-term outlook for the therapy, reflecting investor focus on the upcoming FDA approval outcome.
See More
Investigation into Atkore and Others by Johnson Fistel
- Shareholder Investigation: Johnson Fistel, PLLP is investigating whether executives at Atkore Inc. and others breached their fiduciary duties, allowing shareholders who held shares continuously since specific dates to seek corporate governance reforms.
- Antitrust Allegations: Atkore is accused in a lawsuit of colluding with other PVC pipe manufacturers to engage in price-fixing, which artificially inflated prices and led to a significant decline in pricing once exposed, severely impacting the company's operations.
- Lack of Transparency at Axsome: Axsome Therapeutics faces allegations of failing to disclose critical chemistry and manufacturing issues during the preparation of its New Drug Application, potentially jeopardizing its market prospects and investor confidence.
- CTO's Financial Misrepresentation: CTO Realty Growth is accused of misleading investors about the sustainability of its dividends and using deceptive practices to inflate its financial performance, undermining investor trust in the company's future prospects.
See More
Capricor Therapeutics to Announce Q4 Earnings on March 12
- Earnings Announcement: Capricor Therapeutics, Inc. (CAPR) is set to release its Q4 earnings on March 12 after market close, with a consensus EPS estimate of -$0.55, indicating investor interest in the company's performance outlook.
- Consistent Outperformance: Over the past year, CAPR has consistently beaten both EPS and revenue estimates, demonstrating its stability and growth potential in the market, which enhances investor confidence.
- Forecast Revision Insights: In the last three months, there has been one upward revision to EPS estimates with no downward adjustments, reflecting analysts' optimistic outlook on the company's future performance, which may further drive stock price increases.
- Market Reaction: Following the FDA's review of Capricor's rejected cell therapy, biotech stocks have risen, indicating a positive market response to Capricor's potential breakthroughs, which could create new investment opportunities for the company.
See More
Capricor Stock Jumps 11% Following FDA's Resumption of Review for Muscle-Wasting Drug
- Stock Performance: Capricor's shares rose by 11% following a review of the company's drug for muscle-wasting conditions.
- Drug Review Impact: The positive market reaction is attributed to the favorable assessment of Capricor's treatment, which targets specific health issues.
See More
Capricor Therapeutics Inc. Announces PDUFA Target Action Date for DeramioCel on August 22, 2026
- Target Action Date: The target action date for the drug Deramciclus has been set for August 22, 2026.
- Company Involved: The announcement pertains to Capricor Therapeutics, which is involved in the development of this therapeutic.
See More
Deramiocel Poised to Be First Therapy for DMD's Cardiac and Skeletal Issues
- FDA Review Resumed: The FDA has lifted the Complete Response Letter for Capricor Therapeutics' Deramiocel BLA, resuming its review with a target action date of August 22, 2026, which opens significant market opportunities for the company.
- Clinical Trial Success: Deramiocel achieved its primary endpoint and all Type I error-controlled secondary endpoints in the HOPE-3 Phase 3 trial, demonstrating its potential as the first therapy to address both skeletal and cardiac manifestations of Duchenne muscular dystrophy (DMD).
- Priority Review Eligibility: The company expects to qualify for a Priority Review Voucher (PRV) upon potential approval of Deramiocel, which would expedite its market entry and enhance its competitive position in the rare disease treatment landscape.
- Significant Market Potential: DMD affects approximately 15,000 individuals in the U.S., with limited treatment options currently available; the successful launch of Deramiocel would provide new hope for patients while generating substantial economic returns for Capricor.
See More
Capricor's New Therapy Shows Heart Function Improvement
- Clinical Trial Data: Capricor Therapeutics showcased significant improvements in heart function for Duchenne muscular dystrophy patients in its HOPE-3 trial, with cardiac MRI indicating a notable reduction in fibrosis, suggesting substantial treatment efficacy.
- Key Metric Improvement: After 12 months of treatment, patients with baseline cardiomyopathy experienced a 3.3 percentage-point increase in left ventricular ejection fraction, highlighting Deramiocel's potential to enhance heart health and improve patient quality of life.
- FDA Application Progress: Capricor has submitted a Biologics License Application for Deramiocel to the U.S. FDA, which is currently under review, with a decision expected on August 22, 2026, marking a critical milestone for the company's future prospects.
- Market Reaction: Following the release of new data, CAPR stock rose approximately 2% at the opening bell, yet the market remains cautious about the long-term outlook for the therapy, reflecting investor focus on the upcoming FDA approval outcome.
See More
Investigation into Atkore and Others by Johnson Fistel
- Shareholder Investigation: Johnson Fistel, PLLP is investigating whether executives at Atkore Inc. and others breached their fiduciary duties, allowing shareholders who held shares continuously since specific dates to seek corporate governance reforms.
- Antitrust Allegations: Atkore is accused in a lawsuit of colluding with other PVC pipe manufacturers to engage in price-fixing, which artificially inflated prices and led to a significant decline in pricing once exposed, severely impacting the company's operations.
- Lack of Transparency at Axsome: Axsome Therapeutics faces allegations of failing to disclose critical chemistry and manufacturing issues during the preparation of its New Drug Application, potentially jeopardizing its market prospects and investor confidence.
- CTO's Financial Misrepresentation: CTO Realty Growth is accused of misleading investors about the sustainability of its dividends and using deceptive practices to inflate its financial performance, undermining investor trust in the company's future prospects.
See More
Capricor Therapeutics to Announce Q4 Earnings on March 12
- Earnings Announcement: Capricor Therapeutics, Inc. (CAPR) is set to release its Q4 earnings on March 12 after market close, with a consensus EPS estimate of -$0.55, indicating investor interest in the company's performance outlook.
- Consistent Outperformance: Over the past year, CAPR has consistently beaten both EPS and revenue estimates, demonstrating its stability and growth potential in the market, which enhances investor confidence.
- Forecast Revision Insights: In the last three months, there has been one upward revision to EPS estimates with no downward adjustments, reflecting analysts' optimistic outlook on the company's future performance, which may further drive stock price increases.
- Market Reaction: Following the FDA's review of Capricor's rejected cell therapy, biotech stocks have risen, indicating a positive market response to Capricor's potential breakthroughs, which could create new investment opportunities for the company.
See More
